Cristian Massacesi: AstraZeneca’s priority is on improving the accessibility of cell therapies
Cristian Massacesi, Chief Medical Officer at AstraZeneca, shared a post on LinkedIn:
“Cell therapy is an area with huge potential in oncology, but translating this into therapies that can be used by many more patients around the world means addressing a number of key barriers.
At IO360, Serena De Vita participated in a panel discussion sharing AstraZeneca’s vision for the future of cell therapy. Our priority is on improving the accessibility and scalability of cell therapies, so that more patients can benefit from their transformative potential.
To make this a reality, we’re investing in manufacturing sites, advancing our understanding of disease biology and driving innovation in gene editing, biologics and cell engineering. We are actively working with partners to shape the healthcare ecosystem and continuing to progress our diverse and ambitious cell therapy pipeline.
I am incredibly optimistic for the future of oncology research, and I look forward to cell therapy serving as an integral part of our overarching ambition to one day eliminate cancer as a cause of death.”
Read more posts featuring AstraZeneca at OncoDaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023